Healthcare Wrap: Pacific Edge Surges, Healius and CSL Slide on Earnings Pressure

Pacific Edge (ASX:PEB) was the week’s standout mover, surging 44.83% after a draft US Medicare policy proposed coverage for its Cxbladder Triage and Triage Plus tests in patients with microhematuria, or blood in the urine. Investors cared because Medicare coverage means the test may be paid for by the public insurer, which can unlock sales. Healius (ASX:HLS) went the other way, falling 30.30% after narrowing its profit guidance, warning on labour cost pressure and starting a sale process for Agilex Biolabs. Enlitic (ASX:ENL) dropped 25.00% despite a useful radiology software launch in New Zealand, a sign that contract wins alone were not enough to hold buyers after a strong earlier run.

Diagnostics drove the week

Pacific Edge dominated healthcare trading because the draft Medicare decision goes to the heart of how diagnostics businesses make money in the US. A local coverage determination is a regional Medicare payment rule. In plain English, it helps decide whether doctors can order a test and expect it to be reimbursed. The draft covered hematuria evaluation for the first time and named Cxbladder Triage and Triage Plus. That mattered even more because Triage Plus is priced at US$1,328 per test, well above the company’s older products. Pacific Edge also raised fresh capital through a NZ$25.4 million placement and opened a NZ$6 million retail offer. The money should help it keep operating while it waits for the comment process and final decision. Nexsen (ASX:NXN) rose 18.42% after signing a binding term sheet with GHK Hospital in Hong Kong. The deal gives Nexsen access to a 500-bed hospital and the wider IHH network for clinical validation. That is the testing step needed to show whether a diagnostic works in real hospital settings. Lumos Diagnostics (ASX:LDX) moved the other way, down 16.67%, even after reaching 250 patients in its paediatric FebriDx study and unlocking a US$670,000 milestone payment from BARDA, a US government health agency. The update was useful, but investors may still want to see a finished study and a clear FDA filing before they pay more for the shares.

Commercial deals lifted selected small caps

Bioxyne (ASX:BXN) added 18.57% for the week after locking in a two-year German supply deal worth $50 million with ADREXpharma and announcing a medicinal cannabis flower supply agreement in Costa Rica. Investors liked the size of the German contract because it includes a first-year minimum purchase commitment of $25 million. The stock also held most of its gains after reopening, which suggests buying support remained in place rather than fading quickly. Doctor Care Anywhere (ASX:DOC) fell 9.68% even though it bought a UK weight-loss business with £5.3 million in trailing revenue for only £850,000. The price looked cheap, but the shares still slipped after trading resumed. That can happen when investors worry about integration, or the work needed to combine the new business with the old one, and whether sales will keep flowing after the deal closes.

Big healthcare names faced harder questions

CSL (ASX:CSL) dropped 18.28% after cutting its FY26 revenue and profit outlook and flagging another $5 billion in pre-tax impairments tied to CSL Vifor assets. An impairment is an accounting write-down. It means management now thinks those assets are worth less than previously stated. Investors usually read that as a sign that past growth plans have disappointed. The shares stayed weak after reopening, which showed sellers were still in control. Healius also faced a simple problem. Costs are rising faster than many investors hoped, especially after the Fair Work ruling, while pathology revenue growth remained modest. Pathology is the testing business that handles blood and tissue samples. The company also said the Federal Budget brought no new pathology funding. That left little in the update to offset the cost pressure.

Trials, approvals and cash remained central

Several smaller names traded on clinical and regulatory progress, but the share-price response was mixed. Anteris Technologies (ASX:AVR) climbed 14.37% after confirming US patient enrolment had started in its pivotal DurAVR trial and reminding the market it now holds $283 million in cash after a large January raising. EMVision (ASX:EMV) fell 8.52% even as it expanded its emu™ pivotal trial to include acute ischaemia detection, which means detecting a stroke caused by blocked blood flow. EBR Systems (ASX:EBR) slipped 5.83% after reporting that WiSE implants more than doubled and revenue reached US$2.4 million, because losses and cash burn also increased. Other stocks showed the same pattern. BCAL Diagnostics (ASX:BDX) rose 12.16% on a new CEO appointment aimed at commercial expansion. Radius Care (ASX:RAD) gained 10.53% after posting a 37% lift in profit before tax and a 50% increase in its final dividend. OncoSil Medical (ASX:OSL) lost 11.76% despite promising pancreatic cancer registry data, while AVITA Medical (ASX:AVH) edged up 0.43% as improving revenue, a smaller loss and a BARDA contract balanced each other out. Capital raising stayed busy across the sector. Syntara, Acrux, Avecho, Zimi and Atomo all tapped investors or option holders for cash. That matters because many healthcare companies are still spending before they are earning enough to pay for trials, manufacturing or sales teams. Fresh money can buy time, but it can also dilute existing holders if the company issues a large number of new shares.